Zelira Therapeutics (ASX:ZLD) COGS-to-Revenue : 0.85 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics COGS-to-Revenue?

Zelira Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.05 Mil. Its Revenue for the six months ended in Dec. 2023 was A$0.06 Mil.

Zelira Therapeutics's COGS to Revenue for the six months ended in Dec. 2023 was 0.85.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Zelira Therapeutics's Gross Margin % for the six months ended in Dec. 2023 was 14.55%.

Zelira Therapeutics COGS-to-Revenue Historical Data

The historical data trend for Zelira Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelira Therapeutics COGS-to-Revenue Chart

Zelira Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

0.53

0.61

1.20

Zelira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.87	0.38	1.58	1.07	0.85

Zelira Therapeutics COGS-to-Revenue Calculation

Zelira Therapeutics's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.362	/	0.301
	=	1.20

Zelira Therapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.047	/	0.055
	=	0.85

Zelira Therapeutics (ASX:ZLD) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Zelira Therapeutics's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.047 / 0.055
	=	14.55 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Zelira Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zelira Therapeutics (ASX:ZLD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ZLDAF:USA G1G:Germany

Address

101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website

https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics (ASX:ZLD) Headlines

No Headlines